The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers.
 
Ji Son
No Relationships to Disclose
 
Yingao Zhang
No Relationships to Disclose
 
Mirella Nardo
No Relationships to Disclose
 
Oriol Mirallas
Speakers' Bureau - ROVI
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Almirall; Sanofi
 
Robert Tyler Hillman
Research Funding - Sumitomo Dainippon Pharma Oncology
 
Heather Y. Lin
No Relationships to Disclose
 
Erick Campbell
No Relationships to Disclose
 
Vijaykumar Holla
No Relationships to Disclose
 
Amber Johnson
No Relationships to Disclose
 
Natalie Clark
No Relationships to Disclose
 
Pablo Alvarez-Ballesteros
No Relationships to Disclose
 
Ying Yuan
Consulting or Advisory Role - A2 Biotherapeutics; Abbvie; Amgen; Ascendis Pharma; Bexion; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Enliven Therapeutics; GT Medical Technologies; NeoImmuneTech; NGM Biopharmaceuticals; Repare Therapeutics; SERVIER; Starpax Medical; Vertex
 
Lauren Patterson Cobb
No Relationships to Disclose
 
David Marc Gershenson
Stock and Other Ownership Interests - Bristol-Myers Squibb; Johnson & Johnson; Procter & Gamble
Consulting or Advisory Role - AADi; Genentech; Onconova Therapeutics; SpringWorks Therapeutics; Verastem
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Elsevier as book editor; Royalties from UpToDate for authorship
 
Amir A. Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Gerson Lehrman Group; Guidepoint Global
Consulting or Advisory Role - Adicet Bio; Alkermes; Macrogenics; NuProbe; Theolytics
Research Funding - Aravive (Inst); AstraZeneca (Inst); Avenge Bio (Inst); Bristol-Myers Squibb (Inst); immatics (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Xencor (Inst)
 
Pamela T. Soliman
Honoraria - Medscape
Consulting or Advisory Role - AADi; AADi; Amgen; Clovis Oncology; Eisai; GlaxoSmithKline; WebMD
Research Funding - Incyte (Inst); Novartis (Inst)
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; Bayer; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; GlaxoSmithKline; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; OncLive; Roche; Seagen; Targeted Oncology; Vaniam Group; Vincerx Pharma; Zentalis
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Mereo BioPharma (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; Apeiron Biologics; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Lengo Therapeutics; Loxo; Menarini Group; OnCusp Therapeutics; PACT Pharmaceuticals; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Theratechnologies; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian